title: [Anti-VEGF therapy for peritoneal dissemination model of gastric cancer considering of pharmacokinetics].
abstract: Vascular Endothelial Growth Factor (VEGF) plays an important role in proliferation of cancer cells, angiogenesis and vascular permeability in peritoneal dissemination. Now we investigated the efficacy of anti-VEGF therapy in peritoneal dissemination of gastric cancer considering of pharmacokinetics. We investigated pharmacokinetics of bevacizumab, humanized anti-VEGF monoclonal antibody in subcutaneous xenograft and peritoneal dissemination model of OCUM-2MD3, highly peritoneal-seeding cell line of human scirrhous gastric carcinoma. In the group of intraperitoneal administration, bevacizumab remains in the intraperitoneal cavity and transits slowly to blood pool. On the other hand, in the group of subcutaneous administration, bevacizumab transits faster to blood pool and is accumulated in subcutaneous tumors and peritoneal nodules. Bevacizumab administered intraperitoneally seemed to neutralize intraperitoneal VEGF. Bevacizumab administered in subcutaneous seemed to act on peritoneal wall and control vascular permeability. Systemic administration of anti-VEGF agent will be a potential therapy in peritoneal dissemination of gastric cancer.
authors.affiliation: Dept. of Gastroenterological Surgery, Kanazawa University.
authors.forename: Yasumichi
authors.initials: Y
authors.lastname: Yagi
authors.forename: Sachio
authors.initials: S
authors.lastname: Fushida
authors.forename: Hideto
authors.initials: H
authors.lastname: Fujita
authors.forename: Shinichi
authors.initials: S
authors.lastname: Kinami
authors.forename: Itasu
authors.initials: I
authors.lastname: Ninomiya
authors.forename: Takashi
authors.initials: T
authors.lastname: Fujimura
authors.forename: Masato
authors.initials: M
authors.lastname: Kayahara
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Ohta
authors.forename: Masakazu
authors.initials: M
authors.lastname: Yashiro
authors.forename: Kousei
authors.initials: K
authors.lastname: Hirakawa
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004195:Disease Models, Animal; D018450:Disease Progression; D006801:Humans; D007167:Immunotherapy; D051379:Mice; D008819:Mice, Nude; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000276:immunology* / Q000556:secondary; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology*; D023041:Xenograft Model Antitumor Assays
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab